NASDAQ:SPRB

Spruce Biosciences Competitors

$16.13
+0.55 (+3.53 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.25
Now: $16.13
$16.62
50-Day Range
$14.80
MA: $18.62
$25.79
52-Week Range
$14.18
Now: $16.13
$35.60
Volume22,822 shs
Average Volume45,223 shs
Market Capitalization$375.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Spruce Biosciences (NASDAQ:SPRB) Vs. QURE, HRTX, AMTI, TVTX, SUPN, and GBIO

Should you be buying SPRB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Spruce Biosciences, including uniQure (QURE), Heron Therapeutics (HRTX), Applied Molecular Transport (AMTI), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), and Generation Bio (GBIO).

Spruce Biosciences (NASDAQ:SPRB) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and uniQure's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
uniQure$7.28 million204.82$-124,200,000.00($3.11)-10.66

Spruce Biosciences has higher earnings, but lower revenue than uniQure.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and uniQure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
uniQure011113.00

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 106.58%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Spruce Biosciences.

Profitability

This table compares Spruce Biosciences and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
uniQure-2,738.33%-59.64%-41.47%

Insider & Institutional Ownership

78.3% of uniQure shares are owned by institutional investors. 2.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

uniQure beats Spruce Biosciences on 6 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Heron Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
Heron Therapeutics$145.97 million10.20$-204,750,000.00($2.50)-6.52

Spruce Biosciences has higher earnings, but lower revenue than Heron Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Heron Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
Heron Therapeutics01502.83

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Heron Therapeutics has a consensus target price of $29.60, suggesting a potential upside of 81.71%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Heron Therapeutics.

Profitability

This table compares Spruce Biosciences and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
Heron Therapeutics-216.18%-65.06%-49.14%

Insider & Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats Heron Therapeutics on 5 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Applied Molecular Transport's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Applied Molecular Transport, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
Applied Molecular Transport00403.00

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Applied Molecular Transport has a consensus target price of $68.75, suggesting a potential upside of 63.22%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Applied Molecular Transport.

Profitability

This table compares Spruce Biosciences and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
Applied Molecular TransportN/AN/AN/A

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spruce Biosciences (NASDAQ:SPRB) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Travere Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
Travere Therapeutics$175.34 million8.45$-146,430,000.00($3.46)-7.09

Spruce Biosciences has higher earnings, but lower revenue than Travere Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Travere Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
Travere Therapeutics00503.00

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Travere Therapeutics has a consensus target price of $44.3333, suggesting a potential upside of 80.80%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Travere Therapeutics.

Profitability

This table compares Spruce Biosciences and Travere Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
Travere Therapeutics-40.24%-29.27%-12.25%

Summary

Spruce Biosciences beats Travere Therapeutics on 4 of the 6 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Supernus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
Supernus Pharmaceuticals$392.76 million3.77$113.06 million$2.1013.32

Supernus Pharmaceuticals has higher revenue and earnings than Spruce Biosciences.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Supernus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
Supernus Pharmaceuticals02102.33

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 1.08%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Supernus Pharmaceuticals.

Profitability

This table compares Spruce Biosciences and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
Supernus Pharmaceuticals27.09%20.02%9.67%

Insider & Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Spruce Biosciences on 6 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Insider & Institutional Ownership

63.3% of Generation Bio shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Spruce Biosciences and Generation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce BiosciencesN/AN/AN/AN/AN/A
Generation BioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Generation Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spruce Biosciences00403.00
Generation Bio00603.00

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 55.79%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Generation Bio.

Profitability

This table compares Spruce Biosciences and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spruce BiosciencesN/AN/AN/A
Generation BioN/AN/AN/A

Summary

Generation Bio beats Spruce Biosciences on 2 of the 3 factors compared between the two stocks.


Spruce Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
uniQure logo
QURE
uniQure
1.7$33.14+1.8%$1.49 billion$7.28 million-8.79
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.29+1.9%$1.49 billion$145.97 million-6.60News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.12+16.2%$1.48 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$24.52+4.4%$1.48 billion$175.34 million-14.42Analyst Report
News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$27.97+1.2%$1.48 billion$392.76 million11.61
Generation Bio logo
GBIO
Generation Bio
1.8$26.06+4.4%$1.47 billionN/A0.00Insider Selling
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.96+15.6%$1.43 billionN/A-149.83News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.18+5.3%$1.43 billion$82.27 million-17.51
Kronos Bio logo
KRON
Kronos Bio
1.7$25.41+7.4%$1.42 billionN/A0.00High Trading Volume
Unusual Options Activity
Lockup Expiration
News Coverage
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.46+5.5%$1.42 billion$4.23 million-20.34
Endo International logo
ENDP
Endo International
1.3$6.17+0.5%$1.42 billion$2.91 billion-9.07News Coverage
ATBPD
Antibe Therapeutics
0.1$3.66+6.0%$1.42 billion$7.51 million-6.10
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.36+2.9%$1.41 billion$19.89 million-13.38
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$38.19+6.3%$1.40 billionN/A0.00
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.09+2.2%$1.39 billion$6.20 million-14.07
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.08+7.1%$1.39 billionN/A0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$58.69+2.5%$1.37 billionN/A0.00
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.10+1.8%$1.36 billionN/A-2.94
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.55+1.9%$1.34 billion$73.41 million-4.34News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$28.46+8.9%$1.31 billion$29.54 million-7.55
Shattuck Labs logo
STTK
Shattuck Labs
1.4$30.75+8.2%$1.28 billionN/A0.00Lockup Expiration
News Coverage
OLMA
Olema Pharmaceuticals
1.6$31.73+3.5%$1.27 billionN/A0.00
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.20+1.9%$1.23 billion$4.23 million-9.05
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$33.04+4.0%$1.21 billionN/A-18.36
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.46+5.2%$1.20 billionN/A0.00
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.00+1.3%$1.19 billionN/A-2.72
Innoviva logo
INVA
Innoviva
1.4$11.67+0.3%$1.18 billion$261.02 million5.95
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.95+1.4%$1.16 billionN/A0.00Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$18.93+2.4%$1.15 billion$59.70 million-189.30
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.22+1.4%$1.15 billion$230,000.00-12.20News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.33+0.2%$1.15 billionN/A-8.87News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07+0.0%$1.14 billion$35.22 million-7.35
NKTX
Nkarta
1.8$34.01+5.1%$1.12 billionN/A0.00News Coverage
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.15+9.5%$1.10 billionN/A-6.81News Coverage
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.70+10.4%$1.10 billion$57.05 million0.00
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.86+0.3%$1.10 billion$42.12 million-11.75
Zogenix logo
ZGNX
Zogenix
1.7$18.93+1.8%$1.06 billion$3.65 million-1.99Analyst Upgrade
News Coverage
Omeros logo
OMER
Omeros
1.4$16.93+7.7%$1.05 billion$111.81 million-7.11
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.84+3.0%$1.05 billionN/A-8.06
MannKind logo
MNKD
MannKind
1.4$4.18+1.4%$1.04 billion$63.04 million-19.90
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.27+4.2%$1.03 billion$1.52 million-11.31
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.32+4.7%$1.02 billionN/A-6.68
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.87+5.6%$1.02 billion$120,000.00-3.66
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.75+7.7%$996.53 millionN/A-8.19Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.48+0.6%$977.94 million$122.47 million-26.64
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.15+1.6%$976.94 million$800.40 million22.78News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$36.99+0.0%$972.10 million$20.79 million-12.76Analyst Upgrade
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.01+2.8%$939.14 millionN/A-12.45Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$27.23+4.2%$919.83 millionN/A-25.21News Coverage
Annexon logo
ANNX
Annexon
1.9$23.25+7.2%$887.17 millionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.